<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536234</url>
  </required_header>
  <id_info>
    <org_study_id>ISR-003</org_study_id>
    <nct_id>NCT03536234</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients</brief_title>
  <official_title>A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immune System Regulation AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immune System Regulation AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, randomised, parallel arm phase IIa study. 52 HIV-1 infected patients will be&#xD;
      randomised (in a 1:1 ratio) to either an active group or a control group. The active group&#xD;
      will receive the GnRH analogue triptorelin depot monthly at baseline, week 4 and week 8.&#xD;
      Patients in the active group and in the control group will continue their triple combination&#xD;
      antiretroviral therapy (ART) during the study without changes; unless there is rationale for&#xD;
      change on medical ground. In order to prevent the negative effects of a low testosterone&#xD;
      level, patients in the active group will be offered to receive a single intramuscular depot&#xD;
      injection of testosterone approximately 7 days after triptorelin treatment. This depot&#xD;
      administration will keep the serum testosterone on a normal level until the next triptorelin&#xD;
      dose. This will be repeated when triptorelin is administered at week 4 and week 8. Total&#xD;
      study period is 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline to week 12 in total HIV-1 DNA levels in CD4+ cells in the active group compared to the mean change in the control group.</measure>
    <time_frame>Baseline to 12 weeks time point</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change of the HLA class 1 expression from baseline to week 12 in the active group compared to the mean change in the control group</measure>
    <time_frame>Baseline to 12 weeks time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the CD4+ T-cell counts from baseline to week 12 in the active group compared to the mean change in the control group.</measure>
    <time_frame>Baseline to 12 weeks time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the CD8+ T-cell counts from baseline to week 12 in the active group compared to the mean change in the control group.</measure>
    <time_frame>Baseline to 12 weeks time point</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events in active group compared to control group</measure>
    <time_frame>Baseline to 12 weeks time point</time_frame>
    <description>Adverse events will be presented by Medical Dictionary for Regulatory Activities MedDRA) preferred term (PT) and system organ class (SOC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of patients reporting any adverse events in active group compared to control group</measure>
    <time_frame>Baseline to 12 weeks time point</time_frame>
    <description>Number and percentage of patients reporting any adverse event will be be presented by MedDRA PT and SOC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Triptorelin (GnRH analogue)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin acetate depot</intervention_name>
    <description>3.75 mg triptorelin depot (monthly injections). 3 doses in total</description>
    <arm_group_label>Triptorelin (GnRH analogue)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male gender&#xD;
&#xD;
          2. 18 to 65 years of age, inclusive, at the time of informed consent&#xD;
&#xD;
          3. Ability and willingness to give a written or orally witnessed informed consent&#xD;
&#xD;
          4. HIV-1 infection as documented by HIV antibody test&#xD;
&#xD;
          5. CD4+ cell count &gt;300 cells/μL at screening&#xD;
&#xD;
          6. Total HIV-1 DNA level between 100 to 5000 copies/million PBMC as measured by real-time&#xD;
             PCR within 4 months prior to screening&#xD;
&#xD;
          7. Plasma HIV-1 RNA level &lt;50 copies/mL for the last year (one blip allowed; blip defined&#xD;
             as HIV RNA between 50-150 copies/mL) including a plasma HIV-1 RNA level &lt;50 copies/mL&#xD;
             at screening&#xD;
&#xD;
          8. On triple combination ART (two nucleoside reverse transcriptase inhibitors (NRTI) +&#xD;
             one integrase inhibitor or protease inhibitor or one non-NRTI (NNRTI)) for minimum 36&#xD;
             months (assessed at screening)&#xD;
&#xD;
          9. Currently on continuous triple combination ART as specified above (i.e. no changes in&#xD;
             medication) the past 4 months prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment failure while on triple ART&#xD;
&#xD;
          2. Nadir CD4+ count &lt; 200 cells/μL&#xD;
&#xD;
          3. History of any immunodeficiency disease or condition other than HIV, chronic&#xD;
             clinically significant illness or autoimmune disease&#xD;
&#xD;
          4. Known positive result of screening for hepatitis B (surface antigen positive or&#xD;
             detectable HBV DNA levels in blood) or hepatitis C (HCV RNA positive). Patient treated&#xD;
             for HCV and assessed as cured by treating physician is eligible for the study&#xD;
&#xD;
          5. Serious ongoing infection&#xD;
&#xD;
          6. Abnormal liver biochemical tests &gt; 2 x upper limit of normal (ULN) of aspartate&#xD;
             aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (ALP)&#xD;
&#xD;
          7. Total testosterone, LH or FSH levels at screening assessed as clinically abnormal by&#xD;
             the Investigator&#xD;
&#xD;
          8. Current treatment with testosterone&#xD;
&#xD;
          9. History of any clinically significant kidney disease as determined by the Investigator&#xD;
             or eGFR &lt; 60 mL/min/1.73 m2 at screening. (Patients on dolutegravir with an eGFR&lt;60&#xD;
             may be verified for study inclusion by analysis of cystatin C that should then be&#xD;
             assessed as normal by the Investigator in order for the patient to be eligible)&#xD;
&#xD;
         10. Diabetes mellitus or a fasting plasma blood glucose &gt;7.0 mmol/L at screening&#xD;
&#xD;
         11. Intolerance or contraindication to injectable triptorelin&#xD;
&#xD;
         12. Vital signs, physical examination or lab results that exhibit evidence of acute&#xD;
             illness&#xD;
&#xD;
         13. Known history of moderate or severe depression (see definitions in ICD-10) within the&#xD;
             past 5 years&#xD;
&#xD;
         14. Any congenital or acquired prolongation of the QTc interval and use of any drugs that&#xD;
             has been proven to prolong the QTc interval (Normal QTc interval defined as &lt;450 msec)&#xD;
&#xD;
         15. Involvement in any other drug study within 30 days prior to this study entry&#xD;
&#xD;
         16. An increased PSA (Prostate Specific Antigen) value that is assessed as abnormal by the&#xD;
             treating physician&#xD;
&#xD;
         17. Any medical condition that in the opinion of the Investigator would compromise the&#xD;
             patient's ability to participate in the study&#xD;
&#xD;
         18. Investigator considers the patient unlikely to comply with study procedures,&#xD;
             restrictions and requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ola Winqvist, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ISR AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ola Winqvist, MD, PhD</last_name>
    <phone>+46-70-5427939</phone>
    <email>ola.winqvist@israb.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zentrum für Infektiologie Berlin Prenzlauer Berg</name>
      <address>
        <city>Berlin</city>
        <zip>10439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Hartikainen, MD</last_name>
      <email>hartikainen@zibp.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Karlsplatz</name>
      <address>
        <city>Munich</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Hartikainen, MD</last_name>
      <email>hartikainen@zibp.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Östra sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>416 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Nowak, MD PhD</last_name>
      <email>Piotr.Nowak@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <zip>118 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Nowak, MD PhD</last_name>
      <email>Piotr.Nowak@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Nowak, MD PhD</last_name>
      <email>Piotr.Nowak@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

